J.P. Morgan has initiated coverage of Septerna (NASDAQ:SEPN) with an overweight rating, citing the company’s platform for GPCR drug design.
“Notwithstanding manifold newly actionable GPCR targets, we see Septerna (SEPN) executing a highly attractive pipeline strategy, focused on validated targets
Written by 
